Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Contraceptive Patch Maker Agile Recapitalizes With $45 Million Venture Round

This article was originally published in The Pink Sheet Daily

Executive Summary

Agile said in 2008 its lead product was ready for Phase III trials. Those trials might start soon, now that the firm has found new backers.

You may also be interested in...



Transdermal Delivery Trumps Advisory Panel Concerns About Blood Clots With J&J’s Ortho Evra

With an eye toward keeping the contraceptive patch as an alternative to birth control pills, the Reproductive Health Drugs and Drug Safety and Risk Management Committees voted 19-5 on Dec. 9 that the benefits of the contraceptive patch outweigh its risks.

Financings Of The Fortnight Follows The Money Wherever It Goes

Are VCs looking beyond biopharma to put money into areas like health services and diagnostics? Plus updates on Castlight, Agile Therapeutics, Otonomy, and more.

Financings Of The Fortnight Follows The Money Wherever It Goes

Are VCs looking beyond biopharma to put money into areas like health services and diagnostics? Plus updates on Castlight, Agile Therapeutics, Otonomy, and more.

Related Content

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel